TABLE 1.

Percentages of subjects achieving meningococcal serogroup C rSBA titers ≥8 or ≥128 and rSBA GMTs before and 1, 2, 12, and 24 months following administration of Menitorix at 12 to 14 months of age, by priming MCC vaccine

Time from administration of Menitorix (mo)ParameterResult obtained with the following priming meningococcal serogroup C conjugate vaccine:
MeningitecMenjugateNeisVac-C
PreboostingNo. of subjects716665
GMT (95% CI)3.3 (2.5-4.3)3.7 (2.7-5.0)8.7 (5.7-13.3)
% of subjects with a titer ≥8 (95% CI)17 (9-28)21 (12-33)48 (35-60)
% of subjects with a titer ≥128 (95% CI)6 (2-14)5 (1-13)14 (7-25)
1No. of subjects809176
GMT (95% CI)368.4 (253.7-534.9)467.3 (329.8-662.1)2,085.7 (1,475.6-2,948.0)
% of subjects with a titer ≥8 (95% CI)95 (88-99)96 (89-99)100 (95-100)
% of subjects with a titer ≥128 (95 % CI)86 (77-93)88 (79-94)97 (91-100)
2No. of subjects364543
GMT (95% CI)128.0 (69.4-235.9)343.0 (203.8-577.3)1,413.6 (882.7-2,263.8)
% of subjects with a titer ≥8 (95% CI)89 (74-97)96 (85-99)100 (92-100)
% of subjects with a titer ≥128 (95% CI)64 (46-79)82 (68-92)98 (88-100)
12No. of subjects638466
GMT (95% CI)6.5 (4.2-10.1)7.0 (4.9-10.0)82.3 (48.5-139.9)
% ≥8 (95% CI)33 (22-46)38 (28-49)85 (74-92)
% ≥128 (95% CI)11 (5-22)10 (4-18)55 (42-67)
24No. of subjects354542
GMT (95% CI)3.6 (2.4-5.6)4.3 (2.8-6.7)9.0 (5.0-16.0)
% of subjects with a titer ≥8 (95% CI)23 (10-40)22 (11-37)43 (28-59)
% of subjects with a titer ≥128 (95% CI)3 (0-15)9 (2-21)19 (9-34)